Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers

The development of immune checkpoint inhibitors has altered the landscape of treatment of advanced cancers. These drugs are well tolerated and have shown clinical activity against a wide variety of solid tumors and hematological malignancies. The durability of response is particularly impressive whe...

Full description

Saved in:
Bibliographic Details
Published in:Human vaccines & immunotherapeutics 2016-09, Vol.12 (9), p.2219-2231
Main Authors: Rajan, Arun, Kim, Chul, Heery, Christopher R., Guha, Udayan, Gulley, James L.
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal - administration & dosage
Antineoplastic Agents - administration & dosage
Carcinoma, Non-Small-Cell Lung - therapy
Carcinoma, Renal Cell - therapy
Clinical Trials as Topic
Humans
immune checkpoint inhibitors
immunotherapy
Immunotherapy - methods
melanoma
Melanoma - therapy
nivolumab
non-small cell lung cancer
Product Review
Programmed Cell Death 1 Receptor - antagonists & inhibitors
renal cell carcinoma
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The development of immune checkpoint inhibitors has altered the landscape of treatment of advanced cancers. These drugs are well tolerated and have shown clinical activity against a wide variety of solid tumors and hematological malignancies. The durability of response is particularly impressive when compared to other forms of systemic therapy. Nivolumab (Opdivo) is an IgG4 antibody that causes immune checkpoint blockade by diminishing inhibitory signaling through the programmed death receptor-1 pathway. It is approved for treatment of recurrent non-small cell lung cancer, melanoma, and renal cell carcinoma. Efforts to identify biomarkers of response to nivolumab are ongoing. Clinical trials are also being conducted to determine the benefits of combining nivolumab with other forms of treatment including chemotherapy, molecular-targeted therapy, radiation therapy, and other forms of immune therapy. This review outlines the clinical trials that have led to the emergence of nivolumab as a treatment option for patients with advanced cancers.
ISSN:2164-5515
2164-554X
DOI:10.1080/21645515.2016.1175694